MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$167,806K
Short-term marketable
securities
$147,551K
Receivables from milestones
and royalty assets
$50,000K
Receivables from
collaborative arrangements
$45,539K
Other prepaid and
current assets
$7,564K
Total current assets
$418,460K
Other assets
$24,880K
Operating lease assets
$24,371K
Long-term marketable
securities
$11,128K
Property and equipment,
net
$5,895K
Restricted cash
$836K
Total assets
$485,570K
Total liabilities and
shareholders' equity
$485,570K
Total shareholders'
equity
$296,723K
Unrecognized tax benefits
$85,679K
Total current
liabilities
$38,302K
Future royalty payment
contingency
$32,795K
Long-term operating lease
liabilities
$31,758K
Other long-term
liabilities
$313K
Accumulated deficit
-$859,627K
Additional paid-in capital
$1,156,288K
Accrued
personnel-related expenses
$12,592K
Operating lease
liabilities
$10,945K
Income tax payable
$5,287K
Accrued clinical and
development expenses
$3,373K
Accounts payable
$2,568K
Accrued general and
administrative expenses
$2,052K
Other accrued
liabilities
$1,485K
Accumulated other
comprehensive income
$61K
Ordinary shares, 0.00001
par value per share...
$1K
Back
Back
Balance Sheet
source: myfinsight.com
Theravance Biopharma, Inc. (TBPH)
Theravance Biopharma, Inc. (TBPH)